caa a22 4500 605479054 CHVBK 20210128100408.0 cr unu---uuuuu 210128e20150901xx s 000 0 eng 10.1007/s10741-015-9496-5 doi (NATIONALLICENCE)springer-10.1007/s10741-015-9496-5 A real-world perspective on the prevalence and treatment of heart failure with a reduced ejection fraction but no specific or only mild symptoms [Elektronische Daten] [Farzin Beygui, Manuel Anguita, Ulrich Tebbe, Josep Comin-Colet, Michel Galinier, Peter Bramlage, Eva Turgonyi, Katharina Lins, Lynda Imekraz, Trinidad de Frutos, Michael Böhm] Heart failure (HF) is commonly described according to the severity of symptoms, using the New York Heart Association (NYHA) classification, and the assessment of ventricular function, by measuring the left ventricular ejection fraction (LVEF). It is important to acknowledge, however, that the severity of symptoms does not systematically correlate with the level of ventricular systolic dysfunction. Patients with no or only mild symptoms are still at high risk of HF-related morbidity and mortality. The objective of this review was to summarize the prevalence, characteristics, and treatment of patients with chronic HF and mild or no symptoms and to review epidemiological data from three recent registries conducted in Europe. From a clinical practice perspective, patients with a reduced ejection fraction who have only mild symptoms appear to represent a group of patients for whom the provision of adequate medical care is yet to be optimized. While prescription of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and beta-blockers appears to be consistently high, the use of mineralocorticoid receptor antagonists is more variable and does not appear to be in accordance with the latest clinical guidelines. As approximately half of patients with HF and a reduced LVEF have NYHA class II symptoms, significant reductions in morbidity and mortality could be achieved by more comprehensive treatment of this population. Springer Science+Business Media New York, 2015 Heart failure nationallicence NYHA II nationallicence Pharmacotherapy nationallicence Ejection fraction nationallicence Beygui Farzin Department of Cardiology, University Hospital of Caen Basse-Normandie, Caen, France aut Anguita Manuel Cardiology, Heart Failure and Transplant Program, Hospital University Reina Sofia, Cordoba, Spain aut Tebbe Ulrich Abteilung für Kardiologie, Angiologie und Intensivmedizin, Klinikum Lippe-Detmold, Detmold, Germany aut Comin-Colet Josep Heart Diseases Biomedical Research Group, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain aut Galinier Michel Department of Cardiology A, University Hospital of Toulouse - Rangueil Hospital, Toulouse, France aut Bramlage Peter Institute for Pharmacology and Preventive Medicine, Menzelstrasse 21, 15831, Mahlow, Germany aut Turgonyi Eva Pfizer Ltd., Dorking Rd, KT20 7NS, Tadworth, UK aut Lins Katharina Pfizer Ltd., Dorking Rd, KT20 7NS, Tadworth, UK aut Imekraz Lynda Pfizer France, Paris, France aut de Frutos Trinidad Pfizer Spain SLU, Madrid, Spain aut Böhm Michael Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Homburg, Saar, Germany aut Heart Failure Reviews Springer US; http://www.springer-ny.com 20/5(2015-09-01), 545-552 1382-4147 20:5<545 2015 20 10741 https://doi.org/10.1007/s10741-015-9496-5 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10741-015-9496-5 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Beygui Farzin Department of Cardiology, University Hospital of Caen Basse-Normandie, Caen, France aut NATIONALLICENCE 700 1- Anguita Manuel Cardiology, Heart Failure and Transplant Program, Hospital University Reina Sofia, Cordoba, Spain aut NATIONALLICENCE 700 1- Tebbe Ulrich Abteilung für Kardiologie, Angiologie und Intensivmedizin, Klinikum Lippe-Detmold, Detmold, Germany aut NATIONALLICENCE 700 1- Comin-Colet Josep Heart Diseases Biomedical Research Group, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain aut NATIONALLICENCE 700 1- Galinier Michel Department of Cardiology A, University Hospital of Toulouse - Rangueil Hospital, Toulouse, France aut NATIONALLICENCE 700 1- Bramlage Peter Institute for Pharmacology and Preventive Medicine, Menzelstrasse 21, 15831, Mahlow, Germany aut NATIONALLICENCE 700 1- Turgonyi Eva Pfizer Ltd., Dorking Rd, KT20 7NS, Tadworth, UK aut NATIONALLICENCE 700 1- Lins Katharina Pfizer Ltd., Dorking Rd, KT20 7NS, Tadworth, UK aut NATIONALLICENCE 700 1- Imekraz Lynda Pfizer France, Paris, France aut NATIONALLICENCE 700 1- de Frutos Trinidad Pfizer Spain SLU, Madrid, Spain aut NATIONALLICENCE 700 1- Böhm Michael Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Homburg, Saar, Germany aut NATIONALLICENCE 773 0- Heart Failure Reviews Springer US; http://www.springer-ny.com 20/5(2015-09-01), 545-552 1382-4147 20:5<545 2015 20 10741